WebbioSensAll is a trademark and brand of Domain Therapeutics, Illkirch Graffenstaden 67400, FRANCE. This trademark was filed to EUIPO on Friday, January 17, 2014. The bioSensAll is under the trademark classification: Chemical Products; Computer & Software Services & Scientific Services; The bioSensAll trademark covers Chemicals, or biological or natural … WebDr. Meriem Semache, a scientist at Domain Therapeutics NA, will provide an overview on bioSensAll®, an enhanced bystander bioluminescence resonance energy transfer …

Large‐scale profiling of physiologically relevant naturally occurring ...

Web25 Apr 2024 · The bioSensAll™ technology allows for easier understanding of signaling pathways activated by each candidate molecule, predicting its pharmacological profile. … Web15 Mar 2024 · BioSentinel’s spacecraft is one of 10 CubeSats set to launch aboard Artemis I, the first flight of the Artemis program’s Space Launch System, NASA’s powerful new … matzinger construction

BioSentinel NASA

Web3 Nov 2024 · The bioSensAll platform offers a unique combination of capabilities: it can profile RTK signal transduction; it is compatible with high-throughput screening; and it allows real-time kinetic ... Web25 Apr 2024 · The bioSensAll™ technology allows for easier understanding of signaling pathways activated by each candidate molecule, predicting its pharmacological profile. Web“We are very pleased to have signed this collaboration with Pfizer for the profiling of mutant GPCRs using the bioSensAll™ platform. It is yet another example of the wide applications of the technology, from target validation through to drug discovery and development,” said Pascal Neuville, chief executive officer of Domain Therapeutics. matzikama municipality contact number